Author:
Ball Russell A.,Kinchelow Tosca
Reference15 articles.
1. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection;Wild;Proc Natl Acad Sci U S A,1994
2. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85
3. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
4. Delfraissy JF, Montaner J, Eron J, DeMasi R, Chung J, Drobnes C, et al. Summary of pooled efficacy and safety analyses of enfuvirtide treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral treatment-experienced patients. Abstract 568 presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass
5. Eosinophilic cellulitis;Wells;Br J Dermatol,1979
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献